Production (Stage)
Coeptis Therapeutics Holdings, Inc.
COEP
$8.23
-$0.13-1.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 39.49% | 53.85% | 43.18% | 18.27% | 38.11% |
| Total Depreciation and Amortization | 4.69% | 1.16% | 1.06% | 4.33% | 4.34% |
| Total Amortization of Deferred Charges | 10.73% | -- | -- | -- | -- |
| Total Other Non-Cash Items | -68.56% | -81.94% | -79.32% | -49.72% | -71.04% |
| Change in Net Operating Assets | -128.48% | -107.78% | 1,200.00% | 670.57% | 443.14% |
| Cash from Operations | 4.62% | 8.16% | -8.03% | -27.51% | -62.17% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 200.00% | -- | -- | 171.43% | -- |
| Cash from Investing | 200.00% | -- | -- | 171.43% | -- |
| Total Debt Issued | -25.50% | 184.62% | 300.00% | -126.27% | -- |
| Total Debt Repaid | 61.50% | 46.86% | 68.67% | 16.36% | 30.20% |
| Issuance of Common Stock | -98.27% | -88.66% | -36.42% | -4.67% | -18.92% |
| Repurchase of Common Stock | -- | -- | -71,328.57% | -64,185.71% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 150.20% | 150.00% | 213.90% | 213.90% | 132.54% |
| Cash from Financing | 58.22% | 16.18% | 1,452.34% | -24.71% | 48.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 400.58% | 59.68% | 95.40% | -295.01% | -354.68% |